QCI Interpret for Oncology

Going beyond: Molecular evidence for off-label therapy use

178 views
June 02, 2021
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN Digital Insights explains
•Using molecular pathways to expand therapy options
•Identifying evidence-based therapy options for cancer patients for whom there is no on-label therapy
•Providing confidence with expert-curated, oncologist-reviewed treatment strategies

Related videos

QCI Interpret for Oncology

QCI Interpret One: Oncology variant interpretation just got more precise

1,025 views June 12, 2020

Competing to offer a comprehensive genomic profiling service for solid or...

QCI Interpret for Oncology

Precision medicine for any cancer assay on any platform

1,017 views May 29, 2019

For NGS cancer testing, keeping pace with new discoveries is a serious...

QCI Interpret for Oncology

Managing multiple biomarker therapeutic development

405 views September 12, 2019

For the past two decades, the paradigm in the field has been “one biomarker,...

QCI Interpret for Oncology

FASTQ to final report: Ultra-fast workflow for CGP

371 views July 21, 2022

As our molecular knowledge of cancer continually evolves, a new era in cancer...